Samsung Bioepis Partners with GeoYoung to Launch 'Biosimilar Direct Sales in Korea'

Pharmaceutical distribution company GeoYoung is expanding its specialized distribution area to include biosimilars. As the consignment sales contract with another pharmaceutical company expired, Samsung Bioepis, which has declared its direct sales in Korea, has chosen GeoYoung as its distributor.

Three biosimilars that Samsung Bioepis has started selling directly in Korea this month through a distribution contract with Geo Young: Etoloce, Remaroce, and Adaloce (from left).
[Photo by Samsung Bioepis]

GeoYoung announced on the 22nd that it has signed a third-party logistics (3PL) contract for biosimilar drugs with Samsung Bioepis and has started the first shipment. The target drugs are three autoimmune disease treatment biosimilars (Etoloce, Remaroce, Adaloce) developed by Samsung Bioepis. Until now, these products have been distributed and sold through collaboration with Yuhan Corporation.

However, as the contract expired, Samsung Bioepis decided to start direct sales in Korea from this month and selected GeoYoung as its new distribution partner. This is the first business agreement between the two companies. GeoYoung will handle all distribution processes from receiving, storing, to shipping the biosimilar drugs developed by Samsung Bioepis. More than 200 shipments are expected this month alone, with plans to gradually increase supply volume thereafter.

The largest-scale GeoYoung Cheonan Hub Logistics Center in Korea equipped with cold chain facilities and automation systems
[Photo by GeoYoung]

Samsung Bioepis explained that it highly evaluated GeoYoung’s top-level cold chain system and the largest pharmaceutical distribution capabilities in Korea. Due to the nature of biopharmaceuticals, which are sensitive to temperature and humidity, a top-level cold chain system is essential to prevent product damage and deterioration during transportation. GeoYoung has all the large-scale refrigerated and frozen cold chain facilities and systems optimized for biopharmaceutical storage, centered on the Cheonan logistics center.

Cho Sun-hye, Chairman of GeoYoung, said, "We have been recognized for our specialized biosimilar distribution capabilities based on the in-house facilities of the Cheonan logistics center," adding, "We will continue to do our best to support domestic and international clients by fully mobilizing our independent advanced logistics system and nationwide sales network."

Park Sang-jin, Vice President and Head of Commercial Division at Samsung Bioepis, said, "We have started direct sales of three autoimmune disease treatments to expand treatment opportunities with high-quality biopharmaceuticals for domestic patients," and added, "We look forward to collaborating with GeoYoung, which has the best infrastructure and services in the domestic cold chain sector."

This content was produced with the assistance of AI translation services.